Health System Reform Crucial For ATMPs
Executive Summary
The difficulties in getting advanced therapies, such as Novartis’ CAR-T therapy Kymriah, to patients have shifted and manufacturing capacity is no longer the biggest issue.
You may also be interested in...
Early Advice Could Help Companies Maintain EU Conditional Marketing Authorizations
The number of conditional marketing authorization non-renewals could increase.
El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices
El Salvador has approved a new law that will establish a new regulatory body responsible for authorizing medicines and setting prices.
UK Voluntary Pricing Deal: Commercial Framework To Better Align With New Regulatory Pathways
NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.